Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 17, 2017

Philips reports positive data from ILLUMENATE trial of Stellarex for PAD

Royal Philips has reported positive two-year results from the ILLUMENATE European randomised clinical trial (EU RCT) of the Stellarex 0.035” drug-coated balloon (DCB) to treat peripheral arterial disease (PAD).

Royal Philips has reported positive two-year results from the ILLUMENATE European randomised clinical trial (EU RCT) of the Stellarex 0.035” drug-coated balloon (DCB) to treat peripheral arterial disease (PAD).

Designed to restore and maintain blood flow to arteries, the Stellarex DCB was originally launched by Spectranetics, which was acquired by Philips last month.

The ILLUMENATE trial compared Stellarex with an uncoated balloon angioplasty in 328 patients at 18 centres in Germany and Austria.

Demonstrating the efficacy of Stellarex, the results showed maintenance of blood flow through the treated segment of the diseased artery in 75.9% of patients at 24 months, compared to 61% with an uncoated balloon.

"The addition of Stellarex in the Philips portfolio through the Spectranetics acquisition reinforces our commitment to helping physicians decide, guide, treat and confirm the right therapy for their patients."

The results are said to indicate higher efficacy, patency results, and longer treatment durability for Stellarex.

Royal Philips Image-Guided Therapy Devices business leader Christopher Barys said: “The addition of Stellarex in the Philips portfolio through the Spectranetics acquisition reinforces our commitment to helping physicians decide, guide, treat and confirm the right therapy for their patients.”

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Assessments for the ILLUMENATE EU RCT were performed by angiographic and duplex ultrasound core laboratories, while funding was provided by Philips Spectranetics.

The trial is part of the ILLUMENATE series that comprised five studies for the evaluation of the Stellarex DCB in different groups of patients compared to an uncoated percutaneous transluminal angioplasty (PTA) balloon.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU